Oncoinvent is a clinical stage company committed to developing new innovative radiopharmaceutical products for better treatment options for cancer patients. Radspherin®, the company’s lead product candidate is a novel alpha-emitting radioactive microsphere suspension designed for treatment of metastatic cancers in body cavities. Radspherin® has shown strong and consistent anticancer activity at essentially non-toxic doses in preclinical studies and is anticipated to potentially treat several forms of metastatic cancer. Situated in Oslo, Oncoinvent’s main offices include modern laboratory facilities suitable for cGMP and radiopharmaceutical manufacture for clinical trials and research. The development programs of the company include radiotherapeutic and radioimmunotherapeutic products with focus on alpha-emitting radionuclides for treatment of various solid cancers.
